BioLineRX (BLRX)

• Market cap: $11.3M
• 1 day: -1.24%
• 5 days: 3.25%
• 1 month: -22.63%
• 3 months: -59.28%
• 6 months: -87.24%
• Year to date: -68.88%
• 1 year: -93.09%
• 5 years: -92.84%
• 10 years: -99.73%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 79

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,500% more call options, than puts

Call options by funds: $16K | Put options by funds: $1K

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

0.06% less ownership

Funds ownership: 0.21% [Q3] → 0.15% (-0.06%) [Q4]

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

3% less funds holding

Funds holding: 32 [Q3] → 31 (-1) [Q4]

67% less capital invested

Capital invested by funds: $1.34M [Q3] → $439K (-$904K) [Q4]